Poor
Needs Major Revision
Patient Risk:
Medium
Summary
Multiple extracted claims are either not supported by the provided prescribing information excerpts or are qualitatively overstated (e.g., 'rare cases', 'must watch' travel monitoring, and timing/recurrence after discontinuation). Several material claims about oral steroid-related health risks and specific trial attribution are absent from the supplied label text, preventing confirmation of on-label alignment.
Category Scores
Accurate Statements
Fasenra contains benralizumab.
11 DESCRIPTION
Benralizumab binds to the alpha subunit of the IL-5 receptor (IL-5Rα), expressed on the surface of eosinophils.
12 CLINICAL PHARMACOLOGY (12.1 Mechanism of Action); 1 INDICATIONS AND USAGE (eosinophilic phenotype)
FASENRA is indicated for add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and an eosinophilic phenotype.
1 INDICATIONS AND USAGE (Asthma)
Pharyngitis occurs in a few percent of users of Fasenra.
6 ADVERSE REACTIONS (6.1 Clinical Trials Experience) Table 2 (Pharyngitis 5% vs 3% placebo)
Fasenra is intended for long-term maintenance rather than a brief treatment course.
1 INDICATIONS AND USAGE (add-on maintenance); 14.1 Clinical Studies in Patients with Asthma (SIROCCO 48 weeks; CALIMA 56 weeks)
Fasenra improves lung function as measured by FEV1.
14.1 Clinical Studies in Patients with Asthma (Lung Function; Table 5)
Fasenra allows some patients to reduce their oral steroid dose.
14.1 Clinical Studies in Patients with Asthma (Oral Corticosteroid Reduction; ZONDA)
Eosinophil counts reduce after dosing, including a reduction observed 24 hours post dosing and to a median absolute blood eosinophil count of 0 cells/μL at first time point in SIROCCO and CALIMA.
12 CLINICAL PHARMACOLOGY (12.2 Pharmacodynamics)
Unsupported Statements
In the SIROCCO trial, Fasenra enabled many patients to lower or stop oral steroids while keeping asthma under control.
Label excerpt attributes oral corticosteroid reduction study to ZONDA, not SIROCCO (14.1).
In the CALIMA trial, Fasenra enabled many patients to lower or stop oral steroids while keeping asthma under control.
Label excerpt attributes oral corticosteroid reduction study to ZONDA, not CALIMA (14.1).
Avoiding long-term oral steroid use can reduce the risk of osteoporosis.
No such risk-reduction statements are present in the provided label excerpts.
Avoiding long-term oral steroid use can reduce the risk of diabetes.
No such risk-reduction statements are present in the provided label excerpts.
Avoiding long-term oral steroid use can reduce the risk of weight gain.
No such risk-reduction statements are present in the provided label excerpts.
Rare cases of helminth infections have been reported with Fasenra.
The provided label section on helminths (5.4) discusses clinical trial exclusions and management guidance, not 'rare cases' reporting.
Patients must watch for signs of parasitic infection if they travel to endemic areas.
The provided helminth infection section (5.4) does not include endemic travel 'must watch' instructions or similar wording.
Full clinical effect of Fasenra often occurs four to eight weeks after starting treatment.
No label statement provides this 'often' and 'four to eight weeks' characterization.
Eosinophil levels rebound quickly after discontinuation of Fasenra.
No discontinuation rebound statement is present in the provided label excerpts.
Asthma symptoms and attacks can return within months after discontinuation of Fasenra.
No discontinuation-related timeframe for return of symptoms/attacks is present in the provided label excerpts.
Generic manufacturers and competitors have filed challenges against Fasenra's patents.
Not present in the provided label excerpts (non-clinical/legal assertion).
The patent challenge seeks early entry into the market before the main patent expires in 2030.
Not present in the provided label excerpts (non-clinical/legal assertion).
Contradictions
Important Omissions
No on-label contraindication information was evaluated because the extracted claims do not address contraindications.
Importance:
Low
No on-label boxed warning information was evaluated because the extracted claims do not address boxed warnings.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Medium
Unsupported/overstated safety-related and patient-instruction claims are present (e.g., 'rare cases' framing and 'must watch' endemic travel monitoring for helminths; unsupported systemic risk reductions from steroid avoidance; unsupported discontinuation rebound/recurrence timelines). These could mislead monitoring expectations or patient counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Major Revision
Primary Issue
Multiple materially safety-relevant and trial-attribution claims are absent from or overstated beyond the provided label excerpts.
Suggested Improvement
Remove or rephrase claims not directly supported by the supplied labeling (especially: SIROCCO/CALIMA oral steroid framing, helminth 'rare cases' and endemic travel 'must watch' instructions, steroid-avoidance risk reduction for osteoporosis/diabetes/weight gain, and discontinuation rebound/recurrence timelines). Use only label-supported wording or provide exact label-supported endpoints/timing.